<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Argatroban is a direct thrombin inhibitor approved for the treatment of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> (HIT) type II </plain></SENT>
<SENT sid="1" pm="."><plain>Argatroban is predominantly metabolized in the liver </plain></SENT>
<SENT sid="2" pm="."><plain>It is widely believed that no dosage adjustment is required in patients with <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>, making it a preferred agent in patients on renal replacement therapy (Reddy and Grossman, Ann Pharm 2005;39:1601-1605) </plain></SENT>
<SENT sid="3" pm="."><plain>The elimination half-life of argatroban is approximately 50 min </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> can cause baseline elevation of the PTT and hence it is difficult to monitor the effects of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> such as <z:chebi fb="5" ids="28304">heparin</z:chebi>, lepirudin, or argatroban in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> levels may be used as an alternative for <z:chebi fb="5" ids="28304">heparin</z:chebi> monitoring but plasma levels of argatroban are not commercially available </plain></SENT>
<SENT sid="6" pm="."><plain>A chromogenic antifactor IIa assay could be useful for monitoring argatroban in the presence of a <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, but it is not widely available at present </plain></SENT>
<SENT sid="7" pm="."><plain>We report a patient with <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>, maintained on peritoneal dialysis with HIT, who demonstrated a markedly prolonged half-life when treated with argatroban despite the discontinuation of therapy </plain></SENT>
<SENT sid="8" pm="."><plain>This case also demonstrates the lack of guidelines for the monitoring of argatroban therapy in the presence of an underlying <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
</text></document>